Galderma's Relfydess, Europe's first ready-to-use liquid neuromodulator, received approval for use in frown lines and crow's feet.

Galderma's Relfydess (RelabotulinumtoxinA), Europe's first ready-to-use liquid neuromodulator with PEARL Technology, received approval for use. The positive decision is based on the phase III READY clinical trial program, which demonstrated Relfydess's six-month sustained results and early onset action for frown lines and crow's feet. Galderma is dedicated to expanding its Injectable Aesthetics portfolio.